June 8, 2020 / 12:17 PM / 24 days ago

BRIEF-Lilly Announces Start Of Phase 1 Study For Second Potential COVID-19 Antibody Treatment

June 8 (Reuters) -

* LILLY ANNOUNCES START OF A PHASE 1 STUDY FOR ITS SECOND POTENTIAL COVID-19 ANTIBODY TREATMENT

* ELI LILLY - FIRST HEALTHY VOLUNTEER HAS BEEN DOSED IN A PHASE 1 STUDY OF JS016, LEAD ANTIBODY FROM LILLY’S COLLABORATION WITH JUNSHI BIOSCIENCES

* ELI LILLY AND CO - JUNSHI BIOSCIENCES IS CONDUCTING ITS PHASE 1 STUDY IN CHINA WITH LILLY TO IMMINENTLY BEGIN ITS PHASE 1 STUDY IN UNITED STATES

* ELI LILLY - LILLY WILL EVALUATE EFFICACY OF JS016 AS BOTH A SINGLE AGENT AND A COMBINATION WITH OTHER ANTIBODY TREATMENTS IN COVID-19 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below